Equity Overview
Price & Market Data
Price: $2.06
Daily Change: -$0.01 / 0.49%
Range: $1.97 - $2.10
Market Cap: $35,015,292
Volume: 65,449
Performance Metrics
1 Week: 7.25%
1 Month: %
3 Months: -35.71%
6 Months: 72.50%
1 Year: -32.13%
YTD: -5.91%
Details
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.